Episode Summary

Gregg Ficery, founder of Integgra Advisory Services, discusses his 15-year career in business valuation, explaining when companies need valuations (fundraising, 409A compliance, M&A, litigation) and why profitability matters more than revenue multiples. He shares insights on the current venture funding environment, the AI hype cycle, and his journey from dot-com survivor to valuation expert who has completed over 1,000 valuations.

Pull Quotes

If you're not making any money, you're not worth any money. I've had a company recently that had a very high opinion of their value, and they'd been around for seven years. They'd grown revenue nicely to several million, but never made any money. And they were in a dispute of sorts and wanted to justify a high value. And I'm like, look, I can't do it, especially in a litigation situation, put my reputation online to justify a number that is just unrealistic.

Revenue multiples are much less reliable than even EBITDA multiples. Smaller companies are just generally not as mature. They're riskier, and they deserve higher discount rates on their forecasts. For several reasons, they're just not worth the same multiples as larger public companies.

On the tension between fundraising valuations and employee stock option pricing

The conflict on a lot of the founder's mind is in one breath, they say that they're worth a lot and they want to be worth when they raise money, but on the other side of the coin, they want their options to be priced low. Which one do you want?

It feels a little bit like the early .com days, where there was pets.com. You just added .com to anything and .ai and expect to get a big valuation. There's a lot of exuberance or irrational exuberance, as Alan Greenspan used to say, in the AI world.

On his dot-com experience at youdecide.com

I kind of figured out in my own mind, trying to model this out for the company to say, hey, based on our pricing and the fees that we get and the percentages of click-throughs and buys. It's not just about eyeballs. It's about people buying stuff. We're probably not going to ever make any money here.

Transcript

Todd Merrill:

Hi, welcome to Tales from the SkyLounge. It's a podcast about business, consulting, and venture investing. We get out there in the world, we talk to people who are making it happen, and we get their stories. And today's guest in the SkyLounge, Gregg Ficery. Hey Gregg.

Gregg Ficery:

Hey, how are you, Todd? Thanks for having me on.

Todd Merrill:

Want to go deeper?

Work With Me

Related Episodes

Ep 48 Kumar Ampapathini: What Builders Get Wrong About Capital—From Someone Who's Lived Both Sides

Ep 48 Kumar Ampapathini: What Builders Get Wrong About Capital—From Someone Who's Lived Both Sides

Kumar Ampapathini, a fractional CFO with Wall Street experience and a computer science background, discusses the intersection of technology and finance in startup investing. He explains how AI is transforming business operations, why institutional investors prioritize profitability pathways over pure growth, and how the fractional executive model delivers high-level expertise to early-stage companies at accessible costs.

Ep 06 - Mike Blake: A Journey Through Valuations, Ventures, Visions and Vodka

Ep 06 - Mike Blake: A Journey Through Valuations, Ventures, Visions and Vodka

Mike Blake, founder of High Score Strategies, discusses business valuation methodology, the changing landscape of patent protection, and his journey from venture capital to founding Atlanta's influential Startup Lounge networking series. He shares insights on when valuations help or hinder startup negotiations, the dramatic weakening of patent value through PTAB proceedings, and his recent relocation to Portugal.

Ep44 Niral Shah: A Trauma Surgeon & Entrepreneur Talks Healthcare, AI and What’s Next

Ep44 Niral Shah: A Trauma Surgeon & Entrepreneur Talks Healthcare, AI and What’s Next

Niral Shah, a trauma surgeon and serial entrepreneur, discusses his journey from starting a search engine company during the dot-com boom to becoming a physician entrepreneur focused on healthcare innovation. He shares lessons from shutting down his first startup responsibly, explains why healthcare's structural inefficiencies are ripe for disruption, and identifies promising areas for AI and biotech innovation including at-home diagnostics, drug discovery using incomplete datasets, and real-time health monitoring.